Merck & Co., Inc. sees the individualized neoantigen therapy mRNA-4157, also known as V940, as a key pillar in its oncology development strategy over the next several years, which it said could deliver incremental sales of $20bn by the middle of the next decade, particularly after the presentation of positive follow-up data at the American Society of Clinical Oncology annual meeting.
Merck and partner Moderna, Inc. presented three-year data from the Phase II KEYNOTE-942 study of V940 combined with Keytruda...